OXFORD, United Kingdom and MARLBOROUGH, Mass., March 5, 2019 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following upcoming investor conferences.
Live audio webcasts of Dr. Wrighton-Smith’s presentation on Tuesday, March 12 and fireside chat on Wednesday, March 13 will be available online from the investor relations page of the Oxford Immunotec corporate website at www.oxfordimmunotec.com. Webcast replays will be available approximately 24 hours after the live presentations and will be archived on the website for approximately 90 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company’s T-SPOT®.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
For Media and Investor Inquiries:
VP, Strategy and Investor Relations
Tel: +1 (508) 556-1377